2011年四川省基本药物集中招标中标价格与挂网情况分析

Analysis on the Bidding Drug Prices and Its Sale-permission in the Centralized Bidding of Essential Drug in Sichuan Province in 2011

目的:为完善基本药物招标提供参考与建议。方法:通过四川省药械采购与监管平台收集四川省2011年度基本药物集中招标结果及该品种在四川省的挂网情况,将药品中标价格降幅与挂网厂家数进行对比统计分析。结果:中标化学药品中,只有1家挂网的品规中标价降幅为5.20%,2家及以上挂网品规的平均降价幅度为35.10%。中成药中,只有1家挂网的品规中标价降幅为10.70%,2家及以上挂网品规的平均降价幅度为20.70%。在价格未下降品规中,69.23%的品规只有1家厂家挂网,30.77%有2家及以上厂家挂网。结论:在集中招标制定招标目录时,为了更好的降低药价,应结合临床选择厂家较多的规格/剂型。

OBJECTIVE：To provide reference and suggestions for the improvement of essential drug bidding.METHODS：The centralized bidding of essential drugs and their sale-permission were explored by Sichuan province drugs appliance purchase and supervision platform.The decrease of bidding price and the number of manufacturers who got the sale-permission in Sichuan province were analyzed statistically.RESULTS：The price of bidding chemical drugs in only one manufacturer which got the sale-permission decreased by 5.2% and in more than 2 manufacturers which got the sale-permission decreased by 35.1%.The price of Chinese patent drugs in only one manufacturer which got the sale-permission decreased by 10.7% and in more than 2 manufacturers which got the sale-permission decreased by 20.7%.Only one manufacturer got the sale-permission for 69.23% drugs whose prices didn＇t cut,and two or more manufacturers for 30.77%.CONCLUSION：If we want great price cut in centralized bidding of drug purchase,we should purchase the specification and dosage form which are produced by many manufacturers.